Cala Health Raises $50 Million in Growth Round Led by Vertex Growth Fund and Nexus NeuroTech Ventures

Cala Health, a leader in non-invasive bioelectronic medicine, has closed an oversubscribed $50 million growth round, with Vertex Growth Fund and Nexus NeuroTech Ventures as co-leads. Existing investors such as Action Potential, Johnson & Johnson, Lightstone, Lux Capital, GV, and others also participated in the round. The funding will accelerate the commercialization of Cala's TAPS™ Therapy following a positive Medicare Coverage Determination.

The company aims to increase awareness of its innovative treatment for essential tremor (ET) and Parkinson's disease. Cala Health's TAPS™ Therapy, delivered through the FDA-cleared Cala kIQ System, provides non-invasive, personalized neurostimulation to reduce hand tremors. The company is committed to building clinical evidence to expand patient access, with recent studies showing substantial benefits for ET patients in terms of healthcare resource utilization and costs. With over 7 million people in the United States affected by ET, Cala Health's non-invasive approach offers an alternative to drugs and invasive surgical options.

Founded in 2014, Cala Health is revolutionizing chronic disease care through its wearable neuromodulation therapies. The company's focus on individualized peripheral nerve stimulation has led to the development of FDA-cleared, clinically validated noninvasive devices, allowing patients to regain control over their lives. 

Source: PR NewsWire